Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening.

from http://www.corcept.com/about_corcept

Publications show all

Corcept Therapeutics has published 35 articles.

Patents show all

160Applications103Issued

Clinical Trials show all

10Phase 35Phase 15Phase 23N/A1Other

SEC Filings show all

8-K14910-Q4110-K13D4S-11

Contact Information

149 Commonwealth Drive
Menlo Park, CA 94025
United States

16503273218

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $80,089,47951-1002012-04-10Ipo

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2009-10-30$18,012,959Post_ipo_equityAlta Partners, Longitude Capital, Sutter Hill Ventures
    2001-05-01$28,000,000Venture$113,000,000
    2006-11-15$3,000,000Venture
    2002-12-01$12,800,000Venture$125,000,000
    2010-04-30$7,651,215Post_ipo_equity
    2007-08-20$10,100,000Post_ipo_equityPaperboy VenturesAlta Partners, Sutter Hill Ventures
    2012-04-10$525,305Post_ipo_equity